MX2020002312A - Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin. - Google Patents
Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin.Info
- Publication number
- MX2020002312A MX2020002312A MX2020002312A MX2020002312A MX2020002312A MX 2020002312 A MX2020002312 A MX 2020002312A MX 2020002312 A MX2020002312 A MX 2020002312A MX 2020002312 A MX2020002312 A MX 2020002312A MX 2020002312 A MX2020002312 A MX 2020002312A
- Authority
- MX
- Mexico
- Prior art keywords
- dapagliflozin
- metformin
- proline
- pharmaceutical formulation
- combined pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a combined formulation comprising dapagliflozin L-proline and metformin both. A combined formulation according to the present invention is advantageous for long-term medication because the formulation exhibits not only improved storage stability and property stability and an excellent dissolution rate, but also is highly convenient for dosage. In addition, the combined formulation can be useful for prevention or treatment of diabetes, diabetes-related disease, or diabetic complications.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170126878 | 2017-09-29 | ||
KR1020180079614A KR102369679B1 (en) | 2017-09-29 | 2018-07-09 | Pharmaceutical combination comprising DAPAGLIFLOZIN L-PROLINE and METFORMIN |
PCT/KR2018/011004 WO2019066359A2 (en) | 2017-09-29 | 2018-09-18 | Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020002312A true MX2020002312A (en) | 2020-09-17 |
Family
ID=65901595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020002312A MX2020002312A (en) | 2017-09-29 | 2018-09-18 | Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin. |
Country Status (3)
Country | Link |
---|---|
MX (1) | MX2020002312A (en) |
WO (1) | WO2019066359A2 (en) |
ZA (1) | ZA202001892B (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7919598B2 (en) * | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
EP2498758B1 (en) * | 2009-11-13 | 2018-07-25 | AstraZeneca AB | Bilayer tablet formulations |
US9555001B2 (en) * | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
KR101526825B1 (en) * | 2014-12-23 | 2015-06-08 | 주식회사 한독 | Pharmaceutical Compositions for The Treatment of Diabetes |
CN106924208A (en) * | 2015-12-30 | 2017-07-07 | 深圳翰宇药业股份有限公司 | A kind of compound Dapagliflozin Metformin Extended-release Tablets and preparation method thereof |
-
2018
- 2018-09-18 MX MX2020002312A patent/MX2020002312A/en unknown
- 2018-09-18 WO PCT/KR2018/011004 patent/WO2019066359A2/en active Application Filing
-
2020
- 2020-03-24 ZA ZA2020/01892A patent/ZA202001892B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2019066359A2 (en) | 2019-04-04 |
ZA202001892B (en) | 2023-06-28 |
WO2019066359A3 (en) | 2019-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279040A (en) | Pharmaceutical combination and composition, and combination preparation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof | |
PH12017501222A1 (en) | Glucagon derivatives with improved stability | |
WO2014144130A3 (en) | Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof | |
MX347372B (en) | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator. | |
WO2015128403A3 (en) | An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue | |
MX2013011174A (en) | Prevention of hypoglycaemia in diabetes mellitus type 2 patients. | |
PH12019502655A1 (en) | Acylated insulin compound | |
MX2018002223A (en) | Novel insulin derivatives and the medical uses hereof. | |
PH12019501363A1 (en) | Insulin containing pharmaceutical compositions | |
JP2017502074A5 (en) | ||
JOP20210201A1 (en) | Blood glucose lowering compound | |
RU2016114098A (en) | NEW ANSULIN ANALOGUE DERIVATIVE | |
PH12015501373A1 (en) | Injectable depot formulation comprising optically active tolvaptan and process of producing the same | |
WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
WO2018097570A3 (en) | Pharmaceutical formulation comprising dapagliflozin l-proline | |
PH12020500532A1 (en) | Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin | |
PH12018500817A1 (en) | Pharmaceutical composition comprising metformin and lobeglitazone | |
MX2020002312A (en) | Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin. | |
MX2018011293A (en) | Prolonged release pharmaceutical composition comprising cysteamine or salt thereof. | |
UA115307C2 (en) | APPLICATION OF MEDICINAL PRODUCT CONTAINING RECOMBINANT LECTIN MELINES FOR TREATMENT OF SKIN CANCER | |
PL414785A1 (en) | 3-dodecylsulfanyl-butyric acid to be used as a medicine, preferably to prevent development of insulin immunity and the composition containing 3-dodecylsulfanyl-butyric acid as active substance | |
WO2014195900A3 (en) | Oral pharmaceutical compositions for use in dyslipidemias | |
NZ724595A (en) | Glucokinase activator compositions for the treatment of diabetes | |
MDS20160124U2 (en) | Method for prophylaxis of prolonged lymphorrhagia in the radical treatment of breast cancer in patients with type 2 diabetes |